Penetrating the evidence of EGFR and ALK tyrosine kinase inhibitors for non-small cell lung cancer brain metastases

The brain is a common metastatic site in lung cancer. Approximately one-third of patients will develop brain metastases during the course of their disease. Median overall survival has been reported between 3 and 14.8 months in patients with brain metastases compared to other metastatic sites. In add...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Oncology Pharmacy Practice 2019-04, Vol.25 (3), p.623-637
Hauptverfasser:	Thomas, Christan M, Lee, Chung-Shien
Format:	Artikel
Sprache:	eng
Schlagworte:	Anaplastic Lymphoma Kinase - antagonists & inhibitors Brain Brain cancer Brain Neoplasms - drug therapy Brain Neoplasms - secondary Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Epidermal growth factor Epidermal growth factor receptors ErbB Receptors - antagonists & inhibitors Growth factor receptors Humans Inhibitors Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lymphoma Metastases Metastasis Neuroimaging Non-small cell lung carcinoma Protein Kinase Inhibitors - administration & dosage Survival Toxicity Tyrosine kinase inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!